The Experts below are selected from a list of 36 Experts worldwide ranked by ideXlab platform
Shakir Ali - One of the best experts on this subject based on the ideXlab platform.
-
Genotype–phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region
European Journal of Drug Metabolism and Pharmacokinetics, 2013Co-Authors: Ekta Varshney, Nilanjan Saha, Monika Tandon, Vikesh Shrivastava, Shakir AliAbstract:Identification of polymorphism of cytochrome P450 2C9 (CYP2C9) enzymes in different ethnic populations is important to understand the differences in clinical responses to Drugs. This study determines the CYP2C9 genetic polymorphism in Indian National Capital Region and correlates the phenotype–genotype. Losartan (25 mg) was administered to 107 volunteers to assess CYP2C9 activity, and, on the basis of results, volunteers were categorized as rapid and poor metabolizers. Molecular typing of CYP2C9*1 (wild type), CYP2C9*2 , and CYP2C9*3 (the most common variant) was carried out by single-base primer extension technology for 37 subjects, of which 9 were poor metabolizers, and 28 were rapid metabolizers. 14.28 % of the studied population was identified as poor metabolizer for the category of Drugs metabolized by CYP2C9. Significant difference was observed between the mean ratio (Drug/metabolite) of poor (11.38 ± 5.88) and rapid (1.18 ± 1.11) Drug metabolizers. The study suggests that phenotyping of CYP2C9 is desirable before enrollment of subjects for clinical trials or for deciding Drug Dose Regimen as 14.28 % of study population was found to be poor metabolizer for the category of Drugs metabolized by CYP2C9. This study establishes phenotype–genotype correlation, and proposes to use genotyping or phenotyping to evaluate the status of Drug metabolizing capacity of CYP2C9 as a primary screening procedure before enrolling subjects in clinical trials or in clinical practice.
-
Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region.
European journal of drug metabolism and pharmacokinetics, 2013Co-Authors: Ekta Varshney, Nilanjan Saha, Monika Tandon, Vikesh Shrivastava, Shakir AliAbstract:Identification of polymorphism of cytochrome P450 2C9 (CYP2C9) enzymes in different ethnic populations is important to understand the differences in clinical responses to Drugs. This study determines the CYP2C9 genetic polymorphism in Indian National Capital Region and correlates the phenotype–genotype. Losartan (25 mg) was administered to 107 volunteers to assess CYP2C9 activity, and, on the basis of results, volunteers were categorized as rapid and poor metabolizers. Molecular typing of CYP2C9*1 (wild type), CYP2C9*2, and CYP2C9*3 (the most common variant) was carried out by single-base primer extension technology for 37 subjects, of which 9 were poor metabolizers, and 28 were rapid metabolizers. 14.28 % of the studied population was identified as poor metabolizer for the category of Drugs metabolized by CYP2C9. Significant difference was observed between the mean ratio (Drug/metabolite) of poor (11.38 ± 5.88) and rapid (1.18 ± 1.11) Drug metabolizers. The study suggests that phenotyping of CYP2C9 is desirable before enrollment of subjects for clinical trials or for deciding Drug Dose Regimen as 14.28 % of study population was found to be poor metabolizer for the category of Drugs metabolized by CYP2C9. This study establishes phenotype–genotype correlation, and proposes to use genotyping or phenotyping to evaluate the status of Drug metabolizing capacity of CYP2C9 as a primary screening procedure before enrolling subjects in clinical trials or in clinical practice.
Ekta Varshney - One of the best experts on this subject based on the ideXlab platform.
-
Genotype–phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region
European Journal of Drug Metabolism and Pharmacokinetics, 2013Co-Authors: Ekta Varshney, Nilanjan Saha, Monika Tandon, Vikesh Shrivastava, Shakir AliAbstract:Identification of polymorphism of cytochrome P450 2C9 (CYP2C9) enzymes in different ethnic populations is important to understand the differences in clinical responses to Drugs. This study determines the CYP2C9 genetic polymorphism in Indian National Capital Region and correlates the phenotype–genotype. Losartan (25 mg) was administered to 107 volunteers to assess CYP2C9 activity, and, on the basis of results, volunteers were categorized as rapid and poor metabolizers. Molecular typing of CYP2C9*1 (wild type), CYP2C9*2 , and CYP2C9*3 (the most common variant) was carried out by single-base primer extension technology for 37 subjects, of which 9 were poor metabolizers, and 28 were rapid metabolizers. 14.28 % of the studied population was identified as poor metabolizer for the category of Drugs metabolized by CYP2C9. Significant difference was observed between the mean ratio (Drug/metabolite) of poor (11.38 ± 5.88) and rapid (1.18 ± 1.11) Drug metabolizers. The study suggests that phenotyping of CYP2C9 is desirable before enrollment of subjects for clinical trials or for deciding Drug Dose Regimen as 14.28 % of study population was found to be poor metabolizer for the category of Drugs metabolized by CYP2C9. This study establishes phenotype–genotype correlation, and proposes to use genotyping or phenotyping to evaluate the status of Drug metabolizing capacity of CYP2C9 as a primary screening procedure before enrolling subjects in clinical trials or in clinical practice.
-
Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region.
European journal of drug metabolism and pharmacokinetics, 2013Co-Authors: Ekta Varshney, Nilanjan Saha, Monika Tandon, Vikesh Shrivastava, Shakir AliAbstract:Identification of polymorphism of cytochrome P450 2C9 (CYP2C9) enzymes in different ethnic populations is important to understand the differences in clinical responses to Drugs. This study determines the CYP2C9 genetic polymorphism in Indian National Capital Region and correlates the phenotype–genotype. Losartan (25 mg) was administered to 107 volunteers to assess CYP2C9 activity, and, on the basis of results, volunteers were categorized as rapid and poor metabolizers. Molecular typing of CYP2C9*1 (wild type), CYP2C9*2, and CYP2C9*3 (the most common variant) was carried out by single-base primer extension technology for 37 subjects, of which 9 were poor metabolizers, and 28 were rapid metabolizers. 14.28 % of the studied population was identified as poor metabolizer for the category of Drugs metabolized by CYP2C9. Significant difference was observed between the mean ratio (Drug/metabolite) of poor (11.38 ± 5.88) and rapid (1.18 ± 1.11) Drug metabolizers. The study suggests that phenotyping of CYP2C9 is desirable before enrollment of subjects for clinical trials or for deciding Drug Dose Regimen as 14.28 % of study population was found to be poor metabolizer for the category of Drugs metabolized by CYP2C9. This study establishes phenotype–genotype correlation, and proposes to use genotyping or phenotyping to evaluate the status of Drug metabolizing capacity of CYP2C9 as a primary screening procedure before enrolling subjects in clinical trials or in clinical practice.
Nilanjan Saha - One of the best experts on this subject based on the ideXlab platform.
-
Genotype–phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region
European Journal of Drug Metabolism and Pharmacokinetics, 2013Co-Authors: Ekta Varshney, Nilanjan Saha, Monika Tandon, Vikesh Shrivastava, Shakir AliAbstract:Identification of polymorphism of cytochrome P450 2C9 (CYP2C9) enzymes in different ethnic populations is important to understand the differences in clinical responses to Drugs. This study determines the CYP2C9 genetic polymorphism in Indian National Capital Region and correlates the phenotype–genotype. Losartan (25 mg) was administered to 107 volunteers to assess CYP2C9 activity, and, on the basis of results, volunteers were categorized as rapid and poor metabolizers. Molecular typing of CYP2C9*1 (wild type), CYP2C9*2 , and CYP2C9*3 (the most common variant) was carried out by single-base primer extension technology for 37 subjects, of which 9 were poor metabolizers, and 28 were rapid metabolizers. 14.28 % of the studied population was identified as poor metabolizer for the category of Drugs metabolized by CYP2C9. Significant difference was observed between the mean ratio (Drug/metabolite) of poor (11.38 ± 5.88) and rapid (1.18 ± 1.11) Drug metabolizers. The study suggests that phenotyping of CYP2C9 is desirable before enrollment of subjects for clinical trials or for deciding Drug Dose Regimen as 14.28 % of study population was found to be poor metabolizer for the category of Drugs metabolized by CYP2C9. This study establishes phenotype–genotype correlation, and proposes to use genotyping or phenotyping to evaluate the status of Drug metabolizing capacity of CYP2C9 as a primary screening procedure before enrolling subjects in clinical trials or in clinical practice.
-
Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region.
European journal of drug metabolism and pharmacokinetics, 2013Co-Authors: Ekta Varshney, Nilanjan Saha, Monika Tandon, Vikesh Shrivastava, Shakir AliAbstract:Identification of polymorphism of cytochrome P450 2C9 (CYP2C9) enzymes in different ethnic populations is important to understand the differences in clinical responses to Drugs. This study determines the CYP2C9 genetic polymorphism in Indian National Capital Region and correlates the phenotype–genotype. Losartan (25 mg) was administered to 107 volunteers to assess CYP2C9 activity, and, on the basis of results, volunteers were categorized as rapid and poor metabolizers. Molecular typing of CYP2C9*1 (wild type), CYP2C9*2, and CYP2C9*3 (the most common variant) was carried out by single-base primer extension technology for 37 subjects, of which 9 were poor metabolizers, and 28 were rapid metabolizers. 14.28 % of the studied population was identified as poor metabolizer for the category of Drugs metabolized by CYP2C9. Significant difference was observed between the mean ratio (Drug/metabolite) of poor (11.38 ± 5.88) and rapid (1.18 ± 1.11) Drug metabolizers. The study suggests that phenotyping of CYP2C9 is desirable before enrollment of subjects for clinical trials or for deciding Drug Dose Regimen as 14.28 % of study population was found to be poor metabolizer for the category of Drugs metabolized by CYP2C9. This study establishes phenotype–genotype correlation, and proposes to use genotyping or phenotyping to evaluate the status of Drug metabolizing capacity of CYP2C9 as a primary screening procedure before enrolling subjects in clinical trials or in clinical practice.
Monika Tandon - One of the best experts on this subject based on the ideXlab platform.
-
Genotype–phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region
European Journal of Drug Metabolism and Pharmacokinetics, 2013Co-Authors: Ekta Varshney, Nilanjan Saha, Monika Tandon, Vikesh Shrivastava, Shakir AliAbstract:Identification of polymorphism of cytochrome P450 2C9 (CYP2C9) enzymes in different ethnic populations is important to understand the differences in clinical responses to Drugs. This study determines the CYP2C9 genetic polymorphism in Indian National Capital Region and correlates the phenotype–genotype. Losartan (25 mg) was administered to 107 volunteers to assess CYP2C9 activity, and, on the basis of results, volunteers were categorized as rapid and poor metabolizers. Molecular typing of CYP2C9*1 (wild type), CYP2C9*2 , and CYP2C9*3 (the most common variant) was carried out by single-base primer extension technology for 37 subjects, of which 9 were poor metabolizers, and 28 were rapid metabolizers. 14.28 % of the studied population was identified as poor metabolizer for the category of Drugs metabolized by CYP2C9. Significant difference was observed between the mean ratio (Drug/metabolite) of poor (11.38 ± 5.88) and rapid (1.18 ± 1.11) Drug metabolizers. The study suggests that phenotyping of CYP2C9 is desirable before enrollment of subjects for clinical trials or for deciding Drug Dose Regimen as 14.28 % of study population was found to be poor metabolizer for the category of Drugs metabolized by CYP2C9. This study establishes phenotype–genotype correlation, and proposes to use genotyping or phenotyping to evaluate the status of Drug metabolizing capacity of CYP2C9 as a primary screening procedure before enrolling subjects in clinical trials or in clinical practice.
-
Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region.
European journal of drug metabolism and pharmacokinetics, 2013Co-Authors: Ekta Varshney, Nilanjan Saha, Monika Tandon, Vikesh Shrivastava, Shakir AliAbstract:Identification of polymorphism of cytochrome P450 2C9 (CYP2C9) enzymes in different ethnic populations is important to understand the differences in clinical responses to Drugs. This study determines the CYP2C9 genetic polymorphism in Indian National Capital Region and correlates the phenotype–genotype. Losartan (25 mg) was administered to 107 volunteers to assess CYP2C9 activity, and, on the basis of results, volunteers were categorized as rapid and poor metabolizers. Molecular typing of CYP2C9*1 (wild type), CYP2C9*2, and CYP2C9*3 (the most common variant) was carried out by single-base primer extension technology for 37 subjects, of which 9 were poor metabolizers, and 28 were rapid metabolizers. 14.28 % of the studied population was identified as poor metabolizer for the category of Drugs metabolized by CYP2C9. Significant difference was observed between the mean ratio (Drug/metabolite) of poor (11.38 ± 5.88) and rapid (1.18 ± 1.11) Drug metabolizers. The study suggests that phenotyping of CYP2C9 is desirable before enrollment of subjects for clinical trials or for deciding Drug Dose Regimen as 14.28 % of study population was found to be poor metabolizer for the category of Drugs metabolized by CYP2C9. This study establishes phenotype–genotype correlation, and proposes to use genotyping or phenotyping to evaluate the status of Drug metabolizing capacity of CYP2C9 as a primary screening procedure before enrolling subjects in clinical trials or in clinical practice.
Vikesh Shrivastava - One of the best experts on this subject based on the ideXlab platform.
-
Genotype–phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region
European Journal of Drug Metabolism and Pharmacokinetics, 2013Co-Authors: Ekta Varshney, Nilanjan Saha, Monika Tandon, Vikesh Shrivastava, Shakir AliAbstract:Identification of polymorphism of cytochrome P450 2C9 (CYP2C9) enzymes in different ethnic populations is important to understand the differences in clinical responses to Drugs. This study determines the CYP2C9 genetic polymorphism in Indian National Capital Region and correlates the phenotype–genotype. Losartan (25 mg) was administered to 107 volunteers to assess CYP2C9 activity, and, on the basis of results, volunteers were categorized as rapid and poor metabolizers. Molecular typing of CYP2C9*1 (wild type), CYP2C9*2 , and CYP2C9*3 (the most common variant) was carried out by single-base primer extension technology for 37 subjects, of which 9 were poor metabolizers, and 28 were rapid metabolizers. 14.28 % of the studied population was identified as poor metabolizer for the category of Drugs metabolized by CYP2C9. Significant difference was observed between the mean ratio (Drug/metabolite) of poor (11.38 ± 5.88) and rapid (1.18 ± 1.11) Drug metabolizers. The study suggests that phenotyping of CYP2C9 is desirable before enrollment of subjects for clinical trials or for deciding Drug Dose Regimen as 14.28 % of study population was found to be poor metabolizer for the category of Drugs metabolized by CYP2C9. This study establishes phenotype–genotype correlation, and proposes to use genotyping or phenotyping to evaluate the status of Drug metabolizing capacity of CYP2C9 as a primary screening procedure before enrolling subjects in clinical trials or in clinical practice.
-
Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region.
European journal of drug metabolism and pharmacokinetics, 2013Co-Authors: Ekta Varshney, Nilanjan Saha, Monika Tandon, Vikesh Shrivastava, Shakir AliAbstract:Identification of polymorphism of cytochrome P450 2C9 (CYP2C9) enzymes in different ethnic populations is important to understand the differences in clinical responses to Drugs. This study determines the CYP2C9 genetic polymorphism in Indian National Capital Region and correlates the phenotype–genotype. Losartan (25 mg) was administered to 107 volunteers to assess CYP2C9 activity, and, on the basis of results, volunteers were categorized as rapid and poor metabolizers. Molecular typing of CYP2C9*1 (wild type), CYP2C9*2, and CYP2C9*3 (the most common variant) was carried out by single-base primer extension technology for 37 subjects, of which 9 were poor metabolizers, and 28 were rapid metabolizers. 14.28 % of the studied population was identified as poor metabolizer for the category of Drugs metabolized by CYP2C9. Significant difference was observed between the mean ratio (Drug/metabolite) of poor (11.38 ± 5.88) and rapid (1.18 ± 1.11) Drug metabolizers. The study suggests that phenotyping of CYP2C9 is desirable before enrollment of subjects for clinical trials or for deciding Drug Dose Regimen as 14.28 % of study population was found to be poor metabolizer for the category of Drugs metabolized by CYP2C9. This study establishes phenotype–genotype correlation, and proposes to use genotyping or phenotyping to evaluate the status of Drug metabolizing capacity of CYP2C9 as a primary screening procedure before enrolling subjects in clinical trials or in clinical practice.
